雅本化學(300261.SZ):公司濱海基地二期項目於5月奠基
格隆匯7月5日丨雅本化學(300261.SZ)近期在接待機構調研時表示,除了蘭州基地外,公司濱海基地二期項目於5月奠基,主要產品為創新農藥中間體,未來濱海基地將繼續發揮自身優勢繼續從事農藥全產業鏈產品的佈局和生產。
太倉基地將進行轉型升級,鑑於其目前承擔的生產任務較少,因此具備逐步剝離中間體業務的條件,並且不會對公司的整體生產進度、規模產生較大影響。預計未來兩到三年內,公司將對太倉基地現有生產線升級改造,用較小規模的投入構建以抗病毒系列為主的醫藥產品及大健康產品的生產基地。太倉新項目尚需獲得有關主管部門的審批,公司將根據升級改造的進度,按照監管要求履行審議和信披義務。南通基地為公司旗艦生產基地,將以穩定生產和交付為發展要務,同時探索新產品的規劃落地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.